Center for Molecular Medicine Cologne

Prof. Dr. med. Dr. rer. nat. Michael von Bergwelt-Baildon - Curriculum Vitae

Education and professional career

2017: Professor Hematology and Medical Oncology, Ludwig-Maximilians-University Munich, call accepted.    
2016: DKH Research Consortium Immune checkpoint inhibition in Hodgkin Lymphoma, Head tumor immunology    
2015: CARTime Research Consortium, (CAR T cells in Melanoma-clinical trial) Coordinating Investigator (BMBF)    
2012: Professor and Chair of Hematology, ‚Ronald Finn Chair of Experimental Medicine‘, University of Liverpool, declined
2012: Adjunct Professor of Internal Medicine, University of Cologne    
2011: Senior Consultant (Leitender Oberarzt)    
2009: Board Certification in Infectiology    
2008: Board Certification in Intensive Care Medicine
2008: Director, Cologne Interventional Immunology & scientific Director SCT-Program    
2007: Venia Legendi in Internal Medicine („analysis of the antigen presenting function of B cells: translation to tumor immunotherapy”)    
2007: Consultant    
2006: Board Certification in Internal Medicine, Hematology and Oncology    
2003 - 2009: Head, Max-Eder Junior Research Group, German Cancer Aid    
2002: Dissertation: Dr. rer. nat. (Ph.D.) Biological and Biotechnological Analyses on CD40-activated B cells as Antigen Presenting Cells (honors, University of  Oldenburg)    
2002 - 2007: Internship and Fellowship, Department I of Internal Medicine, University of Cologne (Dir.: Prof. Michael Hallek)    
1999: Board Certification in Emergency Medicine, Lower Saxony    
1999 - 2002: PostDoc Dana-Farber Cancer Institute, Harvard Medical School, Boston    
1997: Dissertation: Dr. med. (M.D.) „Phenotypical and functional characterization of tumor  infiltrating lymphocytes in colorectal carcinoma under stimulation with Interleukin-2 and Interleukin-4 in vitro” (University of Freiburg)    
1997 - 1999: Internship, Department I of Internal Medicine, University of Cologne (Dir.: Prof. Volker Diehl)    
1996: United States Medical Licensure Examination (USMLE) Parts I/II    
Maîtrise de Sciences Biologiques et Médicales (MSBM)    
1996: Approbation in Medicine    
1994 - 1996:
Human Biology at Université de Paris XI    
1988 - 1996:
Medicine at the universities of Freiburg, Münster and Paris XI   

Awards, distinctions and professional activities

2015: Best Abstract Award DGHO (co-author)
2010: Travel Award, American Society for Blood and Marrow Transplantation
2010: Basic Science Award (Abstract O84, last author), European Society for Blood and Marrow Transplantation
2002: Fellow, German José Carreras-Leukemia Foundation
2001: Fellow, Lymphoma Research Foundation of America
1999: 'Travel Award' of the American Society of Hematology
1999: Scientific Award EMSA / University of Prague
1997: Mildred-Scheel Fellow, German Cancer Aid

Selected publications

von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, Hirano N, Anderson KS, Butler MO, Xia Z, Zeng WY, Wucherpfennig KW, Nadler LM, Schultze JL. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 2002; 99: 3319-25.

Schultze JL, Grabbe S, von Bergwelt-Baildon MS. Dendritic cells and CD40-activated B cells: New avenues to cancer immunotherapy. Trends Immunol, 2004; 25: 659-664.

von Bergwelt-Baildon MS, Popov A, Saric T, Chemnitz J, Classen S, Stoffel M,  Fiore F, Roth U, Beyer M, Debey S, Wickenhauser C, Hanisch F.-G-, Schultze JL. CD25 and indoleamine 2,3-dioxygenase are upregulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo. Blood 2006, 108(1):228-37.

Theurich S, Malcher J, Wennhold K, Shimabukuro-Vornhagen A, Chemnitz J, Holtick U, Krause A, Kobe C, Kahraman D, Engert A, Scheid C, Chakupurakal G, Hallek M, von Bergwelt-Baildon M. Brentuximabvedotin combined with donor lymphocyte infusions for early relapse of hodgkin lymphoma after  allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission. J Clin Oncol. 2013 Feb 10;31(5):e59-63. doi: 10.1200/JCO.2012.43.6832.

Shimabukuro-Vornhagen A, Zoghi S, Liebig TM, Wennhold K, Chemitz J, Draube A, Kochanek M, Holtick U, Scheid C, Theurich S, Hallek M, von Bergwelt-Baildon M. Inhibition of protein geranylgeranylation specifically interferes with CD40-dependent B cell activation resulting in the acquisition of tolerogenic features and a reduced capacity to induce T cell immunity. J Immunol. 2014 Nov 15;193(10):5294-305.

Klein Gonzalez N, Wennhold K, Balkow S, Kondo E, Weber T, Garcia-Marquez M, Grabbe S, Bloch W, von Bergwelt-Baildon M*, Shimabukuro-Vornhagen A*. In vitro and in vivo imaging of initial B-T cell interactions in the setting of B-cell based cancer immunotherapy Oncoimmunology. 2015 Jun 17 ;4(9):e1038684,* Cont.equally.

Theurich S, Schlaak M, Steguweit H, Heukamp LC, Wennhold K, Kurschat P, Rabenhorst A, Hartmann K, Schlösser H, Shimabukuro-Vornhagen A, Holtick U, Hallek M, Stadler R, von Bergwelt-Baildon M. Targeting tumor infiltrating B cells in cutaneous T-cell lymphoma. J Clin Oncol. 2016 Apr; 34(12): e110-6.

Weinholt M*, Shimabukuro-Vornhagen A*, Wahl P, Schinköthe T, von Bergwelt-Baildon M*, Bloch W*. Physical exercise modulates the homeostatsis of human regulatory T cells. *shared senior authorship. Journal of Allergy and Clinical Immunology. 2015 Dec; pii:S0091-6749(15)01668-1.

Martin K, Mueller P, Reddy S, Savic S, Kreuzaler M, Khan T, Glatz K, Harbeck N, Nitz U, Gluz O, von Bergwelt-Baildon M, Kreoie P, Christgen M, Zippelius A. Trastuzumab Emtansine (T-DM1) renders HER-2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Science Translational Medicine. 2015 Nov; 7(315): 315ra188.

Shimabukuro-Vornhagen A, Böll B, Kochanek M, Azoulay E, von Bergwelt-Baildon M. Critical Care for Cancer Patients. CA- A Cancer Journal for clinicians. 2016 Jun 27. doi: 10.3322.